ASTRAZENECA PHARMA 2017-18 Annual Report Analysis

Fri, 29 Mar

ASTRAZENECA PHARMA has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

ASTRAZENECA PHARMA Income Statement Analysis

• Operating income during the year rose 5.0% on a year-on-year (YoY) basis.
• The company's operating profit increased by 25.3% YoY during the fiscal. Operating profit margins witnessed a fall and down at 8.1% in FY18 as against 6.8% in FY17.
• Depreciation charges decreased by 6.9% increased by 0.0% YoY, respectively.
• Other income declined by 14.9% YoY.
• Net profit for the year grew by 29.2% YoY.
• Net profit margins during the year grew from 3.6% in FY17 to 4.4% in FY18.

ASTRAZENECA PHARMA Income Statement 2017-18

ASTRAZENECA PHARMA Balance Sheet Analysis

• The company's current liabilities during FY18 stood at Rs 2 billion as compared to Rs 2 billion in FY17, thereby witnessing an increase of 8.7%.
• Current assets rose 28% and stood at Rs 3 billion, while fixed assets fell 14% and stood at Rs 790 million in FY18.
• Overall, the total assets and liabilities for FY18 stood at Rs 5 billion as against Rs 4 billion during FY17, thereby witnessing a growth of 11%.

ASTRAZENECA PHARMA Balance Sheet as on March 2018

ASTRAZENECA PHARMA Cash Flow Statement Analysis

• ASTRAZENECA PHARMA's cash flow from operating activities (CFO) during FY18 stood at Rs 88 million on a YoY basis.
• Cash flow from investing activities (CFI) during FY18 stood at Rs -94 million on a YoY basis.
• Cash flow from financial activities (CFF) during FY18 stood at Rs 0 million, an improvement of 0% on a YoY basis.
• Overall, net cash flows for the company during FY18 stood at Rs -6 million from the Rs 384 million net cash flows seen during FY17.

ASTRAZENECA PHARMA Cash Flow Statement 2017-18

Current Valuations for ASTRAZENECA PHARMA

• The trailing twelve-month earnings per share (EPS) of the company stands at Rs 10.4, an improvement from the EPS of Rs 8.0 recorded last year.
• The price to earnings (P/E) ratio, at the current price of Rs 1,987.8, stands at 103.9 times its trailing twelve months earnings.
• The price to book value (P/BV) ratio at current price levels stands at 10.9 times, while the price to sales ratio stands at 4.7 times.
• The company's price to cash flow (P/CF) ratio stood at 122.3 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

Ratio Analysis for ASTRAZENECA PHARMA

• Solvency Ratios

Current Ratio: The company's current ratio improved and stood at 1.6x during FY18, from 1.3x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

• Profitability Ratios

Return on Equity (ROE): The ROE for the company improved and stood at 10.5% during FY18, from 9.0% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 17.7% during FY18, from 15.9% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

Return on Assets (ROA): The ROA of the company improved and stood at 5.6% during FY18, from 4.8% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

To see how ASTRAZENECA PHARMA has performed over the last 5 years, please visit here.

ASTRAZENECA PHARMA Share Price Performance

Over the last one year, ASTRAZENECA PHARMA share price has moved up from Rs 926.5 to Rs 1,987.8, registering a gain of Rs 1,061.3 or around 114.5%.

(To know more, check out historical annual results for ASTRAZENECA PHARMA and quarterly results for ASTRAZENECA PHARMA)